Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
881 stopped studies mapped to Malignant Intestinal Neoplasm and descendants · 90% state a reason
Over the 881 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05091528 | A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies… | Phase 1 / Phase 2 | terminated | Oct 25, 2021 | Silverback Therapeutics | Sponsor decision based on strategic re-alignment | Sponsor / business decision |
| NCT02960282 | Gut Microbiome in Fecal Samples From Patients With Metastatic Cancer Undergoing… | — | terminated | Nov 9, 2016 | University of Southern California | Slow accrual | Enrollment / accrual |
| NCT03524820 | Cetuximab Therapy for Third Line Rechallenge in Metastatic Colorectal Cancer | Phase 2 | terminated | May 15, 2018 | Hadassah Medical Organization | By Merck | Other (stated, no rule matched) |
| NCT02300922 | Pretargeted Radioimmunotherapy in Metastatic Colorectal Cancer(RITCOLON) | Phase 1 / Phase 2 | terminated | Nov 25, 2014 | Nantes University Hospital | Premature termination of recruitment due to the discontinuation of product supply by the project's… | Drug supply |
| NCT04685551 | Improving Survivorship Among Minority Cancer Dyads | N/A | withdrawn | Dec 28, 2020 | Charles Drew University of Medicine and Science | Study not funded | Funding |
| NCT04670588 | Response Assessment by Circulating Tumor DNA in Patients With Locally Advanced Rectal… | — | withdrawn | Dec 17, 2020 | Medical College of Wisconsin | No accrual. | Enrollment / accrual |
| NCT04596033 | TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy | Phase 1 | terminated | Oct 22, 2020 | Genocea Biosciences, Inc. | Business reasons | Sponsor / business decision |
| NCT02445456 | Feasibility of Sentinel Lymph Node Biopsy in Rectal Cancer(SentiRect) | N/A | terminated | May 15, 2015 | Oxford University Hospitals NHS Trust | Logistical difficulties in recruiting patients led to slower than expected recruitment. Recruitment… | COVID-19 / pandemic |
| NCT01759238 | Chemoradiotherapy for Patients With Oligometastatic Colorectal Cancer(OLGA) | Phase 2 | terminated | Jan 3, 2013 | Universitätsklinikum Hamburg-Eppendorf | unexpectedly slow recruitment | Enrollment / accrual |
| NCT02503111 | The HPV-SAVE Study Team: HPV Screening and Vaccine Evaluation in Men Who Have Sex With Men(HPV-SAVE) | N/A | terminated | Jul 20, 2015 | University Health Network, Toronto | Results from ANCHOR study showed benefit of Treatment over Surveillance in preventing anal… | Other (stated, no rule matched) |
| NCT03970694 | Neoadjuvant Chemoradiotherapy Versus Neoadjuvant Chemotherapy For Unresectable Locally… | Phase 3 | terminated | May 31, 2019 | Sun Yat-sen University | Significant differences in conversion rate as well as R0 resection rate between the two groups. | Other (stated, no rule matched) |
| NCT02837159 | A Mobile Aplication for the Promotion of Healthy Lifestyle Habits in Patients With… | N/A | withdrawn | Jul 19, 2016 | Universidad de Granada | removal of the Phd student due to not obtaining financing | Funding |
| NCT03475680 | Mechanical Bowel Preparation and Oral Antibiotics Before Colon Cancer Surgery(COLONPREP) | Phase 3 | terminated | Mar 23, 2018 | Assistance Publique - Hôpitaux de Paris | lack of inclusions | Other (stated, no rule matched) |
| NCT01507545 | Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO) | Phase 2 | terminated | Jan 11, 2012 | Morphotek | By the sponsor at the end of Stage 1 due to futility. | Efficacy / futility |
| NCT02423785 | Ocular Blood Flow in Colorectal Cancer Patients | — | terminated | Apr 22, 2015 | Medical University of Vienna | Slow recruitment | Enrollment / accrual |
| NCT05156463 | The PAI Trial for Breast and Colon Cancer Survivors | N/A | withdrawn | Dec 14, 2021 | Milton S. Hershey Medical Center | Award not yet received and PI is transferring to a different institution | Other (stated, no rule matched) |
| NCT02102022 | Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on… | Phase 1 / Phase 2 | terminated | Apr 2, 2014 | Polaris Group | not stated | Not stated |
| NCT04627142 | A Study to Test Different Doses of BI 1701963 in Combination With Irinotecan in People… | Phase 1 | terminated | Nov 13, 2020 | Boehringer Ingelheim | Sponsor decision | Sponsor / business decision |
| NCT02588248 | L-Menthol Injection as a Novel Technique During Colonoscopy(MINT-C) | Phase 3 | terminated | Oct 27, 2015 | University Hospitals Cleveland Medical Center | Sponsor/Investigator has decided to close out the study | Investigator |
| NCT03682744 | CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases… | Phase 1 | withdrawn | Sep 25, 2018 | Sorrento Therapeutics, Inc. | Unable to enroll subjects | Enrollment / accrual |
| NCT03875313 | Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid… | Phase 1 / Phase 2 | terminated | Mar 14, 2019 | Calithera Biosciences, Inc | Slow Enrollment | Enrollment / accrual |
| NCT02628535 | Safety Study of MGD009 in B7-H3-expressing Tumors | Phase 1 | terminated | Dec 11, 2015 | MacroGenics | Business decision (not for safety reasons) | Safety / toxicity |
| NCT04119830 | Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable… | Phase 2 | withdrawn | Oct 8, 2019 | Roswell Park Cancer Institute | implementation issues | Other (stated, no rule matched) |
| NCT03099486 | Regorafenib Plus 5-Fluorouracil/Leucovorin Beyond Progression in mCRC | Phase 2 | terminated | Apr 4, 2017 | Fox Chase Cancer Center | Administrative change | Other (stated, no rule matched) |
| NCT02933944 | Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab… | Phase 1 | terminated | Oct 14, 2016 | Targovax ASA | Changing priorities | Other (stated, no rule matched) |
| NCT04034355 | Preventive Treatment of OxaLiplatin Induced peripherAl neuRopathy in Adjuvant Colorectal…(POLAR-A) | Phase 3 | terminated | Jul 26, 2019 | Egetis Therapeutics | On 01 March 2020, the Sponsor decided to place recruitment and dosing of patients on hold following… | Enrollment / accrual |
| NCT02465593 | A Study of PEP503(Radio-enhancer) With Radiotherapy and Chemotherapy for Patients With… | Phase 1 / Phase 2 | terminated | Jun 8, 2015 | PharmaEngine | not stated | Not stated |
| NCT01285102 | Chemoembolization Using Irinotecan in Treating Patients With Liver Metastases From… | Phase 1 | terminated | Jan 27, 2011 | Fox Chase Cancer Center | This study was closed early by the DSMB due to increased toxicity. | Safety / toxicity |
| NCT03050814 | Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With… | Phase 2 | terminated | Feb 13, 2017 | National Cancer Institute (NCI) | Terminated after an unplanned interim efficacy analysis. | Efficacy / futility |
| NCT03654729 | Preventive Treatment of Oxaliplatin Induced Peripheral Neuropathy in Metastatic…(POLAR-M) | Phase 3 | terminated | Aug 31, 2018 | Egetis Therapeutics | On 23 January 2020, the Sponsor announced that the United States (US) Food and Drug Administration… | Other (stated, no rule matched) |
| NCT01995396 | Hartmanns Procedure or Abdominoperineal Excision With Intersphincteric Dissection in…(HAPIrect) | N/A | terminated | Nov 26, 2013 | Region Västmanland | Decision after interims analysis | Other (stated, no rule matched) |
| NCT04985981 | The Prediction of Anastomotic Insufficiency Risk After Colorectal Surgery (PANIC) Study | — | suspended | Aug 2, 2021 | Michel Adamina, MD | Change in core study organization | Other (stated, no rule matched) |
| NCT04001101 | Anti-PD-1 +/- RT for MSI-H Solid Tumors | Phase 2 | withdrawn | Jun 27, 2019 | University of Colorado, Denver | PI has decided to withdraw the study | Other (stated, no rule matched) |
| NCT04165031 | A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation | Phase 1 / Phase 2 | terminated | Nov 15, 2019 | Eli Lilly and Company | The study was terminated due to an unexpected toxicity finding. | Safety / toxicity |
| NCT01324141 | Topical MTS-01 for Dermatitis During Radiation and Chemotherapy for Anal Cancer | Phase 1 | terminated | Mar 28, 2011 | National Cancer Institute (NCI) | Slow, insufficient accrual and failure to meet endpoints. | Enrollment / accrual |
| NCT03661047 | OMega-3 Fatty Acid for the Immune Modulation of Colorectal Cancer(OMICC) | Phase 2 | withdrawn | Sep 7, 2018 | Massachusetts General Hospital | Study will be closed due to zero enrollment in over 2 years. | Enrollment / accrual |
| NCT04778566 | Evaluating the Cologuard Test for Use in Lynch Syndrome | — | withdrawn | Mar 3, 2021 | Geisinger Clinic | Recent discovery of a novel assay that is more likely to be beneficial for patients with Lynch… | Other (stated, no rule matched) |
| NCT04499352 | A Study to Test BI 754091 Alone or in Combination With BI 836880 in People Who Have… | Phase 2 | withdrawn | Aug 5, 2020 | Boehringer Ingelheim | Not due to safety reasons (sponsor decision). | Safety / toxicity |
| NCT04418895 | Neoadjuvant Therapy for Localized Rectal Adenocarcinoma | Phase 2 | withdrawn | Jun 5, 2020 | UNC Lineberger Comprehensive Cancer Center | lack of resources | Other (stated, no rule matched) |
| NCT02319304 | Pelvic Radiotherapy With Concurrent Neoadjuvant FOLFOX for Patients With Newly Diagnosed…(GCC 1314) | Phase 2 | terminated | Dec 18, 2014 | University of Maryland, Baltimore | Slow accrual, PI left instituion | Investigator |
| NCT01505166 | Randomized Phase II Adjuvant Chemotherapy ± FANG™ in Colorectal Carcinoma With Liver…(FANG-CLM) | Phase 2 | terminated | Jan 6, 2012 | Gradalis, Inc. | Terminated (Business Decision to pursue other indications) | Sponsor / business decision |
| NCT01960023 | Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple… | Phase 1 / Phase 2 | withdrawn | Oct 10, 2013 | NSABP Foundation Inc | This registry was planned to report on the Phase II portion of the study. NSABP decided not to… | Other (stated, no rule matched) |
| NCT04430985 | FOLFOX + Immunotherapy With Intrahepatic Oxaliplatin for Patients With Metastatic…(IMMUNOX) | Phase 2 | withdrawn | Jun 16, 2020 | Dorte Nielsen | Problems identifying eligble patients | Other (stated, no rule matched) |
| NCT04831827 | Promoting Equity for Cancer Screening and Follow-up | N/A | withdrawn | Apr 5, 2021 | Mayo Clinic | Insufficient study resources and change in practice. | Other (stated, no rule matched) |
| NCT02173990 | Aflibercept and Chemotherapy as First Line Treatment for Metastatic Colorectal Cancer…(PULSAR) | Phase 2 | terminated | Jun 25, 2014 | Centre Oscar Lambret | Lack of enrollment | Enrollment / accrual |
| NCT03699410 | Observational Study on Rectal Cancer to Verify if Response After Chemo-radiotherapy Can…(LiBReCa) | — | terminated | Oct 9, 2018 | Dimitri Christoforidis | failure to identify complete responders since ctDNA disappears after radiotherapy in most patients. | Other (stated, no rule matched) |
| NCT03176264 | PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients… | Phase 1 | terminated | Jun 5, 2017 | Novartis Pharmaceuticals | The study was terminated early due to company decision. | Sponsor / business decision |
| NCT02163785 | Abdominoperineal Extra-Elevators Rectal Resection for Cancer: Prone Position vs. Supine…(APPRO) | N/A | terminated | Jun 16, 2014 | Hospital Universitario La Fe | insufficient recruitment rate | Enrollment / accrual |
| NCT04620473 | Anlotinib Hydrochloride Combined With Capeox in the Neoadjuvant Treatment of Locally… | Phase 2 | withdrawn | Nov 9, 2020 | Shanghai Minimally Invasive Surgery Center | No approval from ethical committee | Other (stated, no rule matched) |
| NCT04158349 | Intraperitoneal Oxaliplatin in Combo w IV mFOLFIRI for Peritoneal Carcinomatosis From…(IPOX-FOLFIRI) | Phase 1 | terminated | Nov 8, 2019 | University of Utah | PI Decision | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Aug 18, 2022source: clinicaltrials